Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial

被引：0

作者：

Wei, Lai ^{[1
]}

Xie, Qing ^{[2
]}

Huang, Yan ^{[3
]}

Wu, Shanming ^{[4
]}

Xu, Min ^{[5
]}

Tang, Hong ^{[6
]}

Cheng, Jun ^{[7
]}

Gao, Yanhang ^{[8
]}

Mou, Zhuangbo ^{[9
]}

Dou, Xiaoguang ^{[10
]}

Nan, Yuemin ^{[11
]}

Ning, Qin ^{[12
]}

Mao, Yimin ^{[13
]}

Stamm, Luisa ^{[14
]}

Lu, Sophia ^{[14
]}

Dvory-Sobol, Hadas ^{[14
]}

Mo, Hongmei ^{[14
]}

Brainard, Diana ^{[14
]}

Yang, Yongfeng ^{[15
]}

Wang, Guiqiang ^{[16
]}

Hu, Peng ^{[17
]}

Zhang, Lunli ^{[18
]}

Gao, Zhiliang ^{[19
]}

Lin, Feng ^{[20
]}

Shang, Jia ^{[21
]}

Gong, Guozhong ^{[22
]}

Li, Jun ^{[23
]}

Su, Minghua ^{[24
]}

Duan, Zhongping ^{[25
]}

Hou, Jinlin ^{[26
]}

Jia, Jidong ^{[27
]}

机构：

[1] Peking Univ, Peoples Hosp, Inst Hepatol, Beijing, Peoples R China

[2] Ruijin Hosp, Shanghai, Peoples R China

[3] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China

[4] Shanghai Publ Hlth Ctr, Shanghai, Peoples R China

[5] Guangzhou Eighth Municipal Peoples Hosp, Guangzhou, Guangdong, Peoples R China

[6] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[7] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China

[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China

[9] Jinan Infect Dis Hosp, Jinan, Shandong, Peoples R China

[10] China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China

[11] Hebei Med Univ, Hosp 3, Shijiazhuang, Hebei, Peoples R China

[12] Tongji Hosp, Shanghai, Peoples R China

[13] Shanghai Renji Hosp, Shanghai, Peoples R China

[14] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[15] Second Hosp Nanjing, Nanjing, Jiangsu, Peoples R China

[16] Peking Univ, Hosp 1, Beijing, Peoples R China

[17] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China

[18] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[19] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China

[20] Hainan Gen Hosp, Haikou, Hainan, Peoples R China

[21] Henan Prov Peoples Hosp, Zhengzhou, Henan, Peoples R China

[22] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China

[23] Nanjing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China

[24] Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China

[25] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[26] Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[27] Beijing Friendship Hosp, Beijing, Peoples R China

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

637

引用

页码：379A / 379A

页数：1

共 50 条

[21] SOFOSBUVIR/VELPATASVIR FOR 12 WEEKS IN GENOTYPE 1-4 HCV-INFECTED LIVER TRANSPLANT RECIPIENTS
Agarwal, Kosh
Castells, Luis
Mullhaupt, Beat
MacDonald, Douglas C.
McNabb, Brian
Arterburn, Sarah
Camus, Gregory
McNally, John
Brainard, Diana M.
Subramanian, G. Mani
Yip, Christina Sze Man
Huang, Hai Cheng
Gonsalkorala, Enoka
Londono, Maria
Dufour, Jean-Francois
Forns, Xavier
GUT, 2018, 67 : A98 - A99
[22] Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients
Agarwal, Kosh
Castells, Lluis
Mullhaupt, Beat
Rosenberg, William M.
McNabb, Brian L.
Arterburn, Sarah
Camus, Gregory
McNally, John
Brainard, Diana M.
Subramanian, Mani
Gonsalkorala, Enoka
Londono, Maria
Dufour, Jean-Francois
Forns, Xavier
HEPATOLOGY, 2017, 66 : 571A - 571A
[23] EFFICACY AND SAFETY OF SOFOSBUVIR BASED TREATMENTS IN GENOTYPE 3 AND 6 HCV PATIENTS IN SOUTH CHINA
Jiang, Mengfeng
Su, Minghua
Long, Shiyu
Li, Linman
Liang, Dandan
Huang, Jinni
HEPATOLOGY, 2022, 76 : S413 - S414
[24] A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct Acting Antiviral-Experienced Patients with Genotype 1-6 HCV Infection: The POLARIS-4 Study
Zeuzem, Stefan
Flamm, Steven L.
Tong, Myron J.
Vierling, John M.
Pianko, Stephen
Buggisch, Peter
de Ledinghen, Victor
Hyland, Robert H.
Wu, Xiaoru
Svarovskaia, Evguenia S.
Stamm, Luisa M.
Brainard, Diana M.
Subramanian, Mani
McHutchison, John G.
Verna, Elizabeth C.
Bansal, Meena B.
Landis, Charles S.
Strasser, Simone I.
Cooper, Curtis
Kowdley, Kris V.
HEPATOLOGY, 2016, 64 : 59A - 59A
[25] Sofosbuvir/GS-5816+GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-infected Patients
Gane, Edward J.
Hyland, Robert H.
Yang, Yin
Stamm, Luisa M.
Brainard, Diana M.
McHutchison, John G.
Stedman, Catherine A.
HEPATOLOGY, 2015, 62 : 226A - 226A
[26] EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR PLUS RIBAVIRIN FOR 12 OR 24 WEEKS IN GENOTYPE 1 OR 2 HCV-INFECTED JAPANESE PATIENTS WITH PRIOR TREATMENT FAILURE TO DAA-BASED REGIMENS
Izumi, Namiki
Takehara, Tetsuo
Chayama, Kazuaki
Yatsuhashi, Hiroshi
Takaguchi, Koichi
Ide, Tatsuya
Kurosaki, Masayuki
Ueno, Yoshiyuki
Toyoda, Hidenori
Kakizaki, Satoru
Tanaka, Yasuhito
Kawakami, Yoshiiku
Enomoto, Hirayuki
Ikeda, Fusao
Huang, K. C.
De-Oertel, Shampa
McNabb, Brian L.
Camus, Gregory
McNally, John
Brainard, Diana M.
Yip, Christina Sze Man
Huang, Hai Cheng
McHutchison, John G.
Mochida, Satoshi
Mizokami, Masashi
GUT, 2018, 67 : A99 - A99
[27] HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS
Lawitz, E.
Kowdley, K.
Curry, M.
Reau, N.
Nguyen, M.
Kwo, P.
Jacobson, I.
Tran, T. T.
Nahass, R.
Hinestrosa, F.
Herring, R., Jr.
Bennet, M.
Yang, J. C.
Stamm, L. M.
An, Di
Dvory-Sobol, H.
Brainard, D. M.
McHutchison, J. G.
Schiff, E.
Davis, M.
Etzkorn, K.
Chung, R. T.
Pound, D.
Rodriguez-Torres, M.
Reddy, K. R.
Younes, Z.
Gane, E. J.
JOURNAL OF HEPATOLOGY, 2016, 64 : S139 - S140
[28] Efficacy and Safety of Sofosbuvir/Velpatasvir plus Ribavirin for 12 or 24 Weeks in Genotype 1 or 2 HCV-Infected Japanese Patients with Prior Treatment Failure to DAA-Based Regimens
Izumi, Namiki
Takehara, Tetsuo
Chayama, Kazuaki
Yatsuhashi, Hiroshi
Takaguchi, Koichi
Ide, Tatsuya
Kurosaki, Masayuki
Ueno, Yoshiyuki
Toyoda, Hidenori
Kakizaki, Satoru
Tanaka, Yasuhito
Kawakami, Yoshiiku
Enomoto, Hirayuki
Ikeda, Fusao
Huang, K. C.
De-Oertel, Shampa
McNabb, Brian L.
Camus, Gregory
McNally, John
Brainard, Diana M.
McHutchison, John G.
Mochida, Satoshi
Mizokami, Masashi
HEPATOLOGY, 2017, 66 : 111A - 112A
[29] High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals
Lawitz, Erik
Kowdley, Kris
Curry, Michael
Reau, Nancy
Nguyen, Mindie
Kwo, Paul
Jacobson, Ira M.
Tran, Tram
Nahass, Ronald
Hinestrosa, Frederico
Herring, Robert
Bennett, Michael
Llewellyn, Joseph
Yang, Jenny
Stamm, Luisa
Brainard, Diana M.
McHutchison, John G.
Schiff, Eugene
Davis, Mitchell
Etzkorn, Kyle
Chung, Raymond
Pound, David
Rodriguez-Torres, Maribel
Reddy, K. Rajender
Gane, Edward
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S380 - S380
[30] Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients
Pol, Stanislas
Bourliere, Marc
Lucier, Sandy
Hezode, Christophe
Dorival, Celine
Larrey, Dominique
Bronowicki, Jean-Pierre
Ledinghen, Victor D. E.
Zoulim, Fabien
Tran, Albert
Metivier, Sophie
Zarski, Jean-Pierre
Samuel, Didier
Guyader, Dominique
Marcellin, Patrick
Minello, Anne
Alric, Laurent
Thabut, Dominique
Chazouilleres, Olivier
Riachi, Ghassan
Bourcier, Valerie
Mathurin, Philippe
Loustaud-Ratti, Veronique
D'Alteroche, Louis
Fouchard-Hubert, Isabelle
Habersetzer, Francois
Causse, Xavier
Geist, Claire
Rosa, Isabelle
Gournay, Jerome
Saillard, Eric
Billaud, Eric
Petrov-Sanchez, Ventzislava
Diallo, Alpha
Fontaine, Helene
Carrat, Fabrice
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : 39 - 47

← 1 2 3 4 5 →